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Emergence of the newly identified 16S rRNA methy-
lases RmtA, RmtB, and ArmA in pathogenic gram-negative
bacilli has been a growing concern. ArmA, which had been
identified exclusively in Europe, was also found in several
gram-negative pathogenic bacilli isolated in Japan, sug-
gesting global dissemination of hazardous multiple amino-
glycoside resistance genes.
M
ultidrug-resistant gram-negative super microbes
have been emerging worldwide. Since carbapenems
and fluoroquinolones are the last resort against infections
caused by gram-negative bacilli (1,2), the proliferation
and dissemination of such clinical isolates that produce
metallo-β-lactamases and acquire mutations in gyrA and
parC genes have become a global threat (3,4).
Aminoglycosides, including amikacin and tobramycin,
are still potent agents for use against resistant bacilli. One
of the most common resistance mechanisms against
aminoglycosides is the production of aminoglycoside-
modifying enzymes, such as aminoglycoside acetyltrans-
ferases, aminoglycoside phosphorylases, and amino-
glycoside adenyltransferases (5), which are mainly medi-
ated by transferable large plasmids.
Recently, a series of special methylases that protect
microbial 16S rRNA, the main target of aminoglycosides,
was identified in several nosocomial pathogens, including
Pseudomonas aeruginosa (6),  Serratia marcescens (7),
and Klebsiella pneumoniae (8). The newly identified 16S
rRNA methylases RmtA and RmtB were reported from
Japan in 2003 and 2004, respectively (6,7). The gene for
ArmA was initially sequenced in Citrobacter freundii iso-
lated in Poland (GenBank accession no. AF550415) and
later characterized in K. pneumoniae isolated in France in
2003 (8). In 2004, nosocomial spread of ArmA- or RmtB-
producing Escherichia coli and K. pneumoniae was report-
ed from Taiwan (9).
These enzymes are capable of conferring an extraordi-
nary high level of resistance (MIC >512 mg/L) against
most clinically important aminoglycosides as was
observed among aminoglycoside-producing actino-
mycetes, suggesting their probable phylogenic relationship
with the intrinsic 16S rRNA methylases of actinomycetes
(Figure). RmtA shared 82% amino acid identity with
RmtB, but the amino acid sequence similarities between
16S rRNAmethylases isolated from pathogenic gram-neg-
ative microbes and those from aminoglycoside-producing
actinomycetes were relatively low (<33%). From analyses
of the genetic environments of genes encoding 16S rRNA
methylases, the rmtA gene is likely associated with the
mercury-resistant transposon Tn5041 (10); the rmtB gene
was found in the flanking region of Tn3-like structure (7).
The  armA gene was found on a large plasmid which
carries a type 1 integron (8) that mediates various gene
cassettes responsible for multiple antimicrobial resistance.
The structure of these genetic environments implied that
the genes for these 16S rRNA methylases are mediated by
mobile genetic elements carried by transferable large plas-
mids (7,8,10). In fact, the rmtA gene was transferred from
P. aeruginosa strain AR-2 to an aminoglycoside-suscepti-
ble P. aeruginosa strain 105 by conjugation in vitro (6).
The rmtB gene was also transferred from S. marcescens S-
95 to E. coli by transformation (7). The armA gene was
located on a composite transposon Tn1548 (11).
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Figure. Phylogenic relationship among the 16S rRNA methylases.
Each amino acid sequence was subjected to the analysis referred
to the following sources: FmrO, accession no. JN0651; Kmr,
accession no. AB164642; GrmA, accession no. M55520; GrmB,
accession no. M55521; GrmO, accession no. AY524043; Kan,
accession no. AJ414669; Sgm, accession no. A45282; KgmB,
accession no. S60108; NbrB, accession no. AF038408; FMRO,
Q08325; RmtA, (6); RmtB, (7); ArmA, (8); predicted enoyl-CoA
hydratase/carnithine racemase of uncultured marine gamma pro-
teobacterium EBAC20E09, accession no. AAS73112; putative
methylase of Chlorobium tepidum, accession no. AAM72273;
hypothetical protein of Nanoarchaeum equitans, accession no.
AAR39385. The ClustalW program provided by the DNA Data
Bank of Japan (http://www.ddbj.nig.ac.jp/search/clustalw-e.html)
was used in this study.Thus, the growing concern was that these newly identi-
fied aminoglycoside-resistance genes could easily spread
and be further disseminated among the glucose-nonfer-
mentative gram-negative bacilli, including P. aeruginosa
and Acinetobacter spp. and the genera belonging to the
family Enterobacteriaceae.
The Study
We conducted a preliminary screening of the 16S rRNA
methylase-producing bacilli on our gram-negative micro-
bial stock of 2,877 strains isolated from Japanese hospitals
within the past several years. Arbekacin, a semisynthetic
aminoglycoside belonging to the kanamycin group,
requires 2 modifications at the (6′) aminogroup and the
(2′′) hydroxyl group for inactivation, so this agent is not
inactivated by known plasmid-mediated aminoglycoside-
modifying enzymes. Therefore, a high-level arbekacin
resistance (MIC >512 mg/L) was used as a marker for
screening the 16S rRNA methylase-producing strains. All
arbekacin-resistant strains were subjected to polymerase
chain reaction (PCR) analysis to detect rmtA,  rmtB, or
armA, and all strains were PCR positive, except for a strain
of Acinetobacter demonstrating a very high level of resist-
ance to arbekacin (MIC 1,024 mg/L). This strain was later
shown to produce both aminoglycoside 6′-acetyltrans-
ferase and 2′′-adenyltransferase (12), so arbekacin was
inactivated in this strain by both 6′-acetylation and 2′′-
adenylation. Each PCR primer set was used to detect rmtA
and rmtB genes as in our previous reports (6,7). The PCR
primers for amplification of armA were newly designed
(forward: 5′-AGG TTG TTT CCA TTT CTG AG-3′,
reverse: 5′-TCT CTT CCATTC CCTTCT CC-3′), and the
predicted size of the amplicon was 590 bp. These 3 sets of
PCR primers were very reliable in detecting rmtA, rmtB,
and armA genes, respectively. Each PCR amplicon was
then subjected to sequencing analyses on both strands to
confirm its nucleotide sequences for detecting mutations in
the methylase genes.
As reported in our previous study, rmtA and rmtB genes
had been found in P. aeruginosa isolates (6,10) and in 1
strain of S. marcescens (7), respectively. As shown in the
Table, 5 P. aeruginosa strains isolated after our previous
report (6) were rmtA positive. The rmtB gene was addition-
ally identified in 4 K. pneumoniae, 2 E. coli, and 1 K. oxy-
toca strains in Japan. To our surprise, the armA gene,
which had been found in various gram-negative microbial
species belonging to the family Enterobacteriaceae exclu-
sively in Europe as reported by Galimand et al. (13), was
also identified in Japan in 1 strain each of E.  coli,  S.
marcescens, and Acinetobacter sp. Notably, the armA and
rmtB genes were also recently identified in K. pneumoniae
and E. coli in Taiwan (9). Furthermore, the genetic envi-
ronment of the armA gene found in C. freundii isolated in
Poland was similar to that of K. pneumoniae isolated in
France. The genetic environments of the armA gene found
in the 3 Japanese microbial species, E. coli, S. marcescens,
and Acinetobacter sp. (GenBank accession nos. AB116388
and AB117519), were also similar to those found in
Europe (GenBank accession nos. AF550415 and
AY220558). These findings suggest that the ArmA-pro-
ducing gram-negative nosocomial microbes that harbor a
very similar genetic environment carrying the armA gene
have spread globally.
Conclusions
As described previously, arbekacin still shows a very
broad antimicrobial spectrum from gram-positive to gram-
negative nosocomial microbes and has been approved
solely to treat methicillin-resistant Staphylococcus aureus
(MRSA) infections in Japan since 1990 to ensure the pru-
dent use of this agent. The emergence and presence of the
16S rRNA methylase-producing gram-negative bacilli,
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arbekacin has not been listed among the antimicrobial
agents for daily antimicrobial susceptibility testing of
gram-negative microbes.
The use of semisynthetic aminoglycosides, including
arbekacin, in Japanese clinical settings for >10 years may
have promoted the emergence and dissemination of the
16S rRNA methylase-producing gram-negative microbes
in Japan. The large amount of various aminoglycosides
used in livestock-farming environments could have also
been a selective pressure for the emergence and spread of
pathogenic microbes that harbor genetic determinants for
the newly identified 16S rRNAmethylases, as exemplified
by recent isolation of ArmA-producing E. coli from swine
in Spain (GenBank accession no. AY522431).
Since acquisition of multidrug resistance against clini-
cally important antimicrobial agents such as carbapenems
and fluoroquinolones has been developing rapidly world-
wide, the acceleration of even greater aminoglycoside
resistance among gram-negative bacilli promises to
become an actual clinical concern in the near future, just
as vancomycin-resistant enterococci (VRE) did in the
1990s(14). The emergence of gram-positive cocci includ-
ing MRSAand VRE that acquire the 16S rRNAmethylase
could also be a grave clinical matter, although fortunately
no such hazardous microbes have been identified. Thus,
steps must be taken to block further proliferation of these
multidrug-resistant gram-negative super microbes,
including  P. aeruginosa, K. pneumoniae, and Acineto-
bacter spp., as well as multidrug-resistant cocci such as
MRSA and VRE, which have acquired an extraordinarily
high level of resistance to various aminoglycosides
through production of 16S rRNA methylases, especially
in clinical environments.
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